CN Patent
CN102046647A — 制备17-炔基-7-羟基甾族化合物和相关化合物的方法
Assigned to Harbor Therapeutics Inc · Expires 2011-05-04 · 15y expired
What this patent protects
本发明涉及制备17-炔基-7-羟基-甾族化合物、例如17-乙炔基-10R13S-二甲基2,3,4,7.8R,9S,10,11,12,13,14S,15,16,17-十六氢-1H-环戊并[a]菲-3R,7R,17S-三醇(也被称为17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇)的工艺,所述工艺基本上没有在雌激素核受体上具有结合活性的工艺杂质。
USPTO Abstract
本发明涉及制备17-炔基-7-羟基-甾族化合物、例如17-乙炔基-10R13S-二甲基2,3,4,7.8R,9S,10,11,12,13,14S,15,16,17-十六氢-1H-环戊并[a]菲-3R,7R,17S-三醇(也被称为17α-乙炔基-雄甾-5-烯-3β,7β,17β-三醇)的工艺,所述工艺基本上没有在雌激素核受体上具有结合活性的工艺杂质。
Drugs covered by this patent
- regadenoson (Regadenoson) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.